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Summary 
In an effort to improve the treatment of patients with refractory or recurrent lymphoma, we developed a pro- 
tocol using cis-platinum combined with two other agents of known efficacy in these disorders but with differ- 
ing side effects: VP-16 and MGBG. Twenty-six eligible patients were treated with this regimen. There were 
15 men and 11 women with a median age of 54 years (22-73), and performance status of 1 (0-3). Their diag- 
noses were Hodgkin's disease 5 and non-Hodgkin's lymphoma [NHL] 21 which included 11 with diffuse 
histocytic lymphoma [DHL]. The median number of chemotherapy regimens was 2 (1-5); 12 also received 
radiotherapy. Twenty patients are evaluable for response: 15 NHL and 5 Hodgkin's disease. Three patients, 
all of whom had DHL entered complete remission (20%) with a median time to treatment failure of 789 
months. Six NHL (40%) and one Hodgkin's disease (20%) patients entered a partial remission. There were 
three early deaths: one due to progressive disease, one to acute respiratory failure, and one with disease status 
undocumented. Toxicity included leukopenia, thrombocytopenia, anorexia, nausea, vomiting, stomatitis, 
alopecia, renal failure, profound peripheral neuropathy, and hypersensitivity vasculitis. Treatment was 
stopped because of the latter two. These agents are non-crossresistant with doxorubicin-containing regimens. 
The drugs are possibly synergistic and modestly active with moderate to severe toxicity. 
Introduction 
The poor response rate with salvage chemotherapy 
for patients with lymphoma who have either failed 
to enter into remission or who have relapsed from 
their initial combination chemotherapy prompted 
interest in a new type of drug: cis-diamminedichlo- 
roplatinum [1-2]. Following the reports of its effi- 
cacy in these patients as a single agent, it was tested 
in 2 and 3 drug combinations [3-16]. These are 
summarized in Table 1. We have recently described 
the results of such a three drug combination. Cis- 
platin, vinblastine and bleomycin, given to 17 very 
heavily pretreated patients, yielded responses in 9 
(3 complete and 6 partial) [14]. Toxicity included 
severe myelosuppression and mild decrease in crea- 
tinine clearance in patients receiving 2 or more 
courses. There were no drug related deaths. Most 
responders achieved partial remission after the first 
course. Furthermore, many of the nonresponders 
demonstrated a rapid tumor shrinkage but equally 
rapid regrowth and thus could not be called 
responders. These results prompted us to consider 
another combination with cisplatinum, and we 
selected VP-16 and MGBG. VP-16 is a synthetic 
congener of podophyllotoxin, the crystalline ex- 
tract of the plant podophyllum peltatum. It was 
shown to have a response rate of 14% in 64 patients 
with Hodgkin's and 23-32% in over 100 patients 
with non-Hodgkin's lymphoma [17]. Its major tox- 
232 
Table 1. Literature survey 
Non-Hodgkin's Hodgkin's disease Unknown distribution 
Study Ref Drugs Total Eval CR % PR ~ %Total Eval CR ~ PR % %TotalEval  CR ~ PR ~ %Total 
resp resp resp 
Rossof 1 PT 25 17 1 6 6 8 1 13 1 13 26 
Cavalli 2 PT 31 19 5 26 26 8 1 13 13 
Bender 21 VP-16 20 19 1 5 7 37 42 
Kroner 5 VP-16 20 13 5 38 38 7 5 71 71 
Knight 22 MGBG 54 44 1 2 8 18 20 10 3 30 30 
Warrell 23 MGBG 46 27 10 37 37 13 6 46 46 
Judson 3 PT VP-16 25 17 5 29 4 24 53 
Kaplan 4 PT VP-16 58 53 6 11 11 21 32 
Kroner 5 PT VP-16 22 18 5 38 38 7 5 71 71 
Von Heyden 6 PT VP-16 15 4 1 25 25 11 2 18 18 
Fosser 7 PT VP-16 PRED 18 6 2 33 33 12 3 25 2 17 41 
Dabich PT VP-16 MGBG 27 15 3 20 6 40 60 5 1 20 20 
Williams 8 PT VP-16 CCNU 25 18 3 17 17 7 1 14 14 
BCNU 
MTX-L 
PT VP-16 ARA-C 16 15 1 7 9 60 67 
PT AMSA MGBG 37 30 13 44 44 
PT VDS MGBG 16 14 2 14 6 43 57 
PT VM-26 ARA-C 21 21 2 10 7 33 43 
PT VM-26 BCNU 20 13 2 15 5 38 53 
BL 
DEX 
PT VLB BL 17 14 3 21 2 14 35 3 3 100 100 
PT VLB BL 13 13 5 38 38 









Drugs: BCNU = Carmustine,CCNU = Lomustine,BL-Bleomycin 
MTX-L = Methotrexate with leucovorin rescue 
VDS = Vindesine,VLB = Velban,VM-26 = Teniposide 
PRED = Prednisone,DEX = Dexamethasone 
AMSA = Amsacrine,ARA-C = Cytosine arabinoside 
Headings: Eval = No. of evaluable patients 
CR = No. of complete responders 
PR = No. of  partial responders 
icity is reversible myelosuppression, particularly 
leukopenia and anemia [ 17-19]. Methylglyoxal bis 
guanylhydrazone is a drug in which there is renewed 
interest. It had been used previously as methy-gag 
[20-23]. Warrell noted partial responses in 6 of 
13 evaluable patients with refractory Hodgkin's 
disease and 10 of 27 patients with non-Hodgkin's 
lymphomas [23]. Toxicity was mild and consisted 
mainly of muscular weakness, myalgia, mucosi- 
tis, and diarrhea. Myelosuppression was minimal 
which made this agent attractive for use in combi- 
nation with myelotoxic drugs. 
tocol was used to treat patients with refractory lym- 
phoma, both Hodgkin's and non-Hodgkin's type. 
We are reporting our results and toxicity in 27 of 
these patients. 
Treatment 
The protocol is outlined in Table 2, which also illus- 
trates the adjustment for hematologic nadir and 
renal impairment. The courses were repeated every 
28 days. 
From January, 1981 until January, 1985 this pro- 
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Table 2. Protocol 
Drugs Dose Days o f  cycle 
Cisplatin 60 m g / M  2 1 
VP-16 80 m g / M  2 1,2,3 
MGBG 500 m g / M  2 1,8,15 
Modifications: hematologic nadirs 
PMNS Platelets C IS P T / M 2 V P - 1 6 / M / M  2 MGBG 2 
> 1500/mm 3 > 100,000/mm 3 
500-999/mm 3 50-74,999/mm 3 
< 499 < 49,999 
Renal 
Rise in maximum serum creatinine 
above baseline (mg %) 
< .5  
> . 5 b u t  < .75  





















Material and methods 
Eligibility criteria 
All patients with histologically confirmed refracto- 
ry Hodgkin ' s  or non-Hodgkin ' s  lymphoma who 
had measurable disease and performance status 
equal to 3 or better by SWOG group criteria were 
eligible for entry onto this protocol.  Patients with 
Hodgkin ' s  disease should have received a doxorubi- 
cin containing regimen prior to entry onto this 
study. There were no age restrictions and no limita- 
tion on the number  of  previous regimens. The ini- 
tial WBC count was to be equal to or greater than 
3000/cu m m  and the platelet count equal to or 
greater than 75,000/cu mm. The serum creatinine 
could be no greater than 1.5 rag%. The creatinine 
clearance following hydration was to be greater 
than 50 cc/minute.  Patients could have no evidence 
of  active central nervous system involvement. I f  
such disease were present, specific treatment aimed 
at CNS lymphoma was to be underway before the 
patient could begin chemotherapy with this pro- 
gram. Patients were to be 3 weeks past previous 
chemotherapy or radiation therapy at the onset. 
The period was 4 weeks for patients who had re- 
ceived nitrosoureas. It was necessary for patients to 
give informed consent in keeping with our institu- 
tional policies and a signed statement to that effect 
was to be a part  of  the record. We planned to give 
patients allopurinol unless they were allergic to this 
medication. 
Pretreatment requirements 
Pretreatment evaluation included history and phys- 
ical examination with documentat ion of  symptoms,  
disease activity, tumor measurements,  and perfor- 
mance status. Labora tory  parameters included 
CBC with differential and platelet count, uric acid, 
electrolytes, magnesium, and liver function studies 
(SGOT, SGPT,  LDH,  alkaline phosphatase and 
bilirubin). To establish the renal function we ob- 
tained BUN and serum creatinine, urinalysis with 
microscopic examination of  the sediment and a 24 
hour urine for creatinine and protein. IVP or renal 
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ultrasound was used to rule out hydronephrosis. 
Other investigations included chest x-ray and elec- 
trocardiogram. 
Criteria for  response 
Complete remission (CR) was defined as the disap- 
pearance of all clinical evidence of tumor on physi- 
cal examination, x-ray or biochemical evaluation 
for more than 1 month. Partial remission (PR) was 
50~ or greater decrease by physical examination, 
roentgenogram and /or  CT scan in the sum of the 
products of the perpendicular diameters of all 
measured lesions lasting more than 1 month. There 
could be no simultaneous increase in the size of any 
lesion or appearance of any new lesions. A partial 
remission in metastatic liver disease consisted of a 
50~ reduction in the summation of  all liver mea- 
surements below the costal margin and improve- 
ment of abnormal liver function tests to normal. 
Minor response was a 25~ decrease in all measura- 
ble disease but less than that required for a partial 
remission. Stabilization was a less than 25~ 
decrease or increase in measurable disease for more 
than 2 months. For progression (Progr) there was 
to be the appearance of either new lesions or a 
greater than 25~ increase in measurable disease. 
The subjective response was measured by the 
SWOG performance scale. The duration of re- 
sponse was measured from the initiation of  the 
study until a 25~ increase in the sum of  all tumor 
measurements was reached. An adequate trial was 
defined as one cycle of therapy with objective dis- 
ease progression or 2 cycles of therapy. 
Results 
The individual patients are described in Table 3 and 
toxicity in Table 4. Although 27 patients were 
entered onto this protocol, one patient with Hodg- 
kin's disease was ineligible because he had not 
received a doxorubicin containing regimen prior to 
this therapy. The 26 eligible patients included 15 
men and 11 women with a median age of 54 years, 
range 22 to 73, and a performance status of 1, range 
0 to 3. There were 5 with Hodgkin's  disease, and 21 
with non-Hodgkin's  lymphoma, sub-divided into 
11 diffuse histiocytic lymphoma (DHL), 3 diffuse 
mixed lymphoma (DML), 3 diffuse poorly dif- 
ferentiated lymphoma (DPDLL), 2 nodular poorly 
differentiated lymphocytic lymphoma (NPDLL) 
and 2 well differentiated lymphocytic lymphoma 
(WDLL). Bone marrow involvement was present in 
6 and bone involvement in 5 patients. These pa- 
tients were heavily pretreated. The median number 
of  previous chemotherapy regimens was 2 with a 
range of 1-5 .  Twelve of  the 26 patients had also 
received radiotherapy at some time. Two patients 
were treated with less than 1 course, 10 patients 1 
course, seven 2, two 3, three 5, two 6 and one 8 
courses of cisplatin, VP-16, and MGBG. Patients 
in PR continued to be treated as long as they 
responded. Twenty of the twenty six eligible pa- 
tients, 15 with NHL and 5 with Hodgkin's  disease, 
were evaluable for response. There were three com- 
plete remissions in patients with DHL [3/15 NHL 
= 20~ with time to treatment failure 5, 7 89  and 
42 months. There were 3 early deaths, one due to 
disease progression prior to completion of the first 
course, and one immediately after. Unfortunately 
the patient was transferred to another hospital and 
the measurable disease was not documented. The 
third patient died of  acute respiratory failure, the 
question of its relationship to chemotherapy is not 
resolved. Two patients had therapy discontinued 
because of profound peripheral neuropathy and 
hypersensitivity vasculitis, and one refused to com- 
plete the first course. 
Treatment in 67 courses resulted in a median 
white count of 1800/cu mm, range 100-14,200, 
platelets 93,000/cu mm, range 3200- 391,000. The 
doses were sufficiently high that only 3 patients 
received the prescribed chemotherapy. Although 
MGBG should have been given, the usual adjust- 
ment for myelosuppression was the withholding of  
Day 15 and/or  Day 8 MGBG. This was done even 
on the first course. There was severe drug induced 
renal failure in one patient and modest renal im- 
pairment in two others. In one of these there was a 
response to modulation of dose. Infections oc- 
curred in 9 of 67 courses and bleeding in 3. Severe 
nausea and vomiting was noted at some time in one- 
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Table 3. Individual patient characteristics 
# Diag Age Sex Race Previous chemotherapy Rad P . S . B . M .  Bone Sites of disease No. of Outcome Duration 
courses months 
2 Hodgkins 22 F W MOPP,  VELB, COP, No 1 Lung, Nodes 1 PROGR 
CHLOP,  C-MOPP 
3 26 F W MOPP,  CHOP,  PVB Yes 1 + Pancreas, Nodes, Flank 2 PR 
5 26 M W MOPP,  C-MOPP No 1 Nodes, Kidney 3 INELIG 
11 26 F W MOPP,  ABVD Yes 0 Breast mass, Chest wall, 1 PROGR 
Mediastinum 
18 22 M W MOP-BAP No 1 Adrenal, Mediastinum, 1 PROGR 
Ext Abd dis 
W Yes 0 Nodes 1 PROGR 
N No 2 + + Liver, Nodes 2 PROGR 
12 54 M W No 0 + Nodes, Liver, ABD Mass 1 PR 
9 NPDLL 47 F W No 1 ABD Mass, Nodes 8 PR 
W No 1 + Nodes 2 PROGR 
W No 0 + Nodes 3 PR 
No 2 + Nodes, Liver, Lung 1 NE-RFT 
Yes 1 Abd Mass < 1 NE-TOX ~ 
No 1 Small bowel, Nodes 6 PR 
Yes 1 + Lung, Pleura, Chest wall 2 PR 
No 1 Liver, Nodes, ABD Mass 5 PR 
Yes 0 Lung, Nodes 6 CR 7 1/2 
Brain 1 Abd wall, CSF 2 PROGR 
Yes 1 Abd 2 PROGR 
No I + Tonsils, Nodes, Liver 2 PROGR 
No 1 Nodes 1 NE-ED 
Yes 1 Nodes, Skin, CNS, Abd mass 5 CR 5 
Yes 0 + Nodes, Palate 5 CR 42 
Yes 0 + Nodes 1 PROGR 
Yes 0 Liver, Nodes 1 NE-TOX 2 
No 3 Tonsils, Nodes < 1 NE-ED 
Yes 1 Abd mass, Nodes 1 NE-ED 
RFT-1 ISevere neuropathy 
2Hypersensitivity vasculitis 
23 24 F MOPP,  ABVD, BCVPP 
7 WDLL 58 M COP, COP, VCR/CHL,  
AOP,  P O A C H  
CHOP,  COP, COAP, COMLA 
CHOP,  X2, PVB, C C N U /  
PRO, C H L / P R E D  
16 37 M CHOP,  PVB, C H L / C C N U  
17 DPDLL 51 F CHOP 
19 68 M W CHOP,  COP 
22 61 M W CHOP 
13 DML 66 M W BACOP,  CYTOXAN 
15 60 M W COP, CHLOP,  CHOP 
21 54 F W CHOP 
1 DHL 52 M B CHOP,  COP, ARA-C-MTX 
4 41 M W BACOP,  ARA-C-MTX 
6 63 F W CHOP,  COP-BL 
8 31 M W CHOP,  HIGH DOSE ADRIA 
10 70 F W CHOP 
14 54 M W CHOP 
20 49 F W H I G H  DOSE ADRIA 
24 43 F W CHOP 
25 61 M W CHOP,  MOPP 
26 73 M B CHOP 
27 51 M W BACOP 
Summary: CR-3, PR-7, PROGR-10, NE-ED-3, TOX-2, INELIG-1, 
Drug combinations 




Adriamycn, Vincristine, Prednisone 
Cytosine Arabinoside-Met hotrexate 
Bleomycin, Adriamycin, Cyclophosphamide, Vincristine, 
Prednisone 
BCVPP: BCNU, Cyclophosphamide, Vinblastine, Procarbazine, 
Prednisone 
CCNU/PRO:  CCNU/Procarbazine  






Cyclophosphamide, Adriamycin, Vincristine, Prednisone 
Cyclospbosphamide, Vincristine, Procarbazine, Pred- 
nisone 













Cyclophosphamide, Vincristine, Methotrexate, 
Levcovorin, Adriamycin 
Cyclophosphamide, Vincristine, Prednisone 
Cyclophosphamide, Vincristine, Prednisone, Bleomycin 
Adriamycin, Vincristine, Prednisone, Cytosine 
Arabinoside, Cyclophosphamide 
Nitrogen Mustard, Vincristine, Procarbazine, Bleomy- 
cin, Adriamycin, Prednisone 
Nitrogen Mustard, Vincristine, Procarbazine, Pred- 
nisone 
Prednisone, Vincristine, Cytosine Arabinoside, Cyclo- 
phosphamide, Adriamycin 




Table 4. Toxicity 
WBC median 1800/cu mm (100-14,200) 
Platelets 93,000/cu mm (3200-391,000) 
_ 3 N/V or > 5 emesis/day 
>_3 Anorexia or 5-10% wt loss 
>- 3 Stomatitis or > 3 discrete ulcers 
Hepatic 
>_2 Renal or Bun 51-75 or creatinine 
2.6-3.0 mg/dl. 
>_ 3 CNS or severe paresthesias 
>_ 3 Skin or moist disquamation 
with ulceration 
>_ 2 Alopecia or pronounced hair loss 
Infections 9/67 courses 









* Responded to change in dose: 1/3 patients 
third of the patients, but severe diarrhea occurred 
in only 1 patient and stomatitis in 2. As noted there 
was discontinuation of protocol due to severe peri- 
pheral neuropathy in one patient and to skin hyper- 
sensitivity in another. Alopecia was not a problem. 
Hypoglycemia was not seen. 
Discussion 
The addition of other agents to cis-platinum seems 
to confer some added efficacy, since results with 
cis-platinum as a single agent were modest with few 
complete responders (Table 1). Unfortunately, the 
small numbers of patients and the relatively large 
numbers of protocols with different doses and 
schedules preclude the use of statistical analysis to 
sort out the contribution of each agent. For exam- 
ple, Judson and Wiltshaw, [3] i.e., used a dose 
schedule of cis-platinum 50 mg/m 2 i.v. daily with 
hydration plus VP-16 100 mg/m 2 i.v. days 1-3, 
repeated every 3 weeks, whereas Kaplan et al. [4] 
administered cis-platinum 20 mg/m 2 and VP-16 80 
mg/m 2, both daily for 5 days every 3-4 weeks. 
The Judson and Wiltshaw regimen produced the 
best complete response rate (29%) in patients with 
non-Hodgkin's lymphoma, but it was only of 12 
weeks duration. The combination of cis-platinum, 
cytosine arabinoside and decadron also resulted in 
a significant complete response (26%) with a more 
durable remission. Like these latter investigators 
we achieved our best responses in patients with 
large cell lymphoma, all of whom had been treated 
initially with doxorubicin containing regimens, sug- 
gesting these drugs are non-cross resistant with the 
front line therapy. One of the responders had re- 
ceived multiple combinations [3] prior to this one. 
The remissions were fairly long-lived with a median 
time to treatment failure of 7 V2 (5-42) months, but 
the CR rate (20%) is not as good than that of the 
cytosine arabinoside combination. Toxicity was 
moderately severe and, mainly, reversible. Renal 
impairment persisted in 2/3 patients. 
In summary, the combination of cis-platinum, 
VP-16 and MGBG constitutes a modestly active 
and moderately to severely toxic regimen for the 
management of patients with relapsed lymphoma. 
Its efficacy in this group of patients might warrant 
further exploration of these potentially synergistic 
drugs in protocols with refractory aggressive lym- 
phomas. 
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